VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IWWM-11 2022 | Ibrutinib monotherapy in WM: long-term follow-up data

Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term follow-up data of ibrutinib monotherapy in patients with Waldenström’s macroglobulinemia (WM), commenting on the overall response rate (ORR) and very good partial response (VGPR) observed, as well as the impact of CXCR4 mutations on patient response.This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting fees or research funds from Abbvie, AstraZeneca, BeiGene, Casma, Cellectar, Janssen, Pharmcyclics, Roche, TG Therapeutics.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter